Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial
- 4 February 2016
- journal article
- research article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 130 (6) , 433-440
Abstract
Platelets play an important role in the activation of coagulation. P2Y12 receptor inhibition may be beneficial in inflammatory states. Prasugrel, a potent irreversible inhibitor of P2Y12 receptor-induced platelet activation may reduce activation of coagulation in a human LPS (lipopolysaccharide) model. A double-blind, randomized, crossover trial with a minimum washout period of 6 weeks was performed. Sixteen subjects were randomly assigned to a treatment group that received prasugrel or placebo 2 h before infusion of a bolus of LPS (2 ng/kg of body weight), whereas four subjects were assigned to a control group receiving prasugrel or placebo without LPS. hcDNA (histone-complexed DNA), coagulation and platelet-specific parameters were measured by enzyme immunoassay. Leucocyte aggregate formation was analysed by flow cytometry, and thromboelastometry was performed. LPS infusion markedly activated coagulation. However, prasugrel did not reduce changes in prothrombin fragments 1 and 2 (F1+2), thrombin–antithrombin complexes, microparticle-associated tissue factor, CD40 ligand, P-selectin, platelet–leucocyte aggregation, hcDNA levels or the coagulation profile measured by thromboelastometry. hcDNA plasma levels increased approximately 6-fold after LPS infusion in both treatment groups, but not in the control groups. Potent irreversible P2Y12 inhibition by prasugrel does not affect LPS-induced coagulation activation. The 6-fold increased hcDNA plasma levels after infusion of LPS indicates the formation of neutrophil extracellular traps during sterile inflammation.Keywords
This publication has 46 references indexed in Scilit:
- Platelets: at the nexus of antimicrobial defenceNature Reviews Microbiology, 2014
- Use of antiplatelet agents in sepsis: A glimpse into the futureThrombosis Research, 2014
- The role of platelets in sepsisThrombosis and Haemostasis, 2014
- The coagulation system and its function in early immune defenseThrombosis and Haemostasis, 2014
- Prasugrel Metabolites Inhibit Neutrophil FunctionsThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouseThrombosis and Haemostasis, 2012
- Prehospitalization Antiplatelet Therapy Is Associated With a Reduced Incidence of Acute Lung InjuryChest, 2011
- Antiplatelet drugs and outcome in mixed admissions to an intensive care unit*Critical Care Medicine, 2010
- Coagulation interventions in experimental human endotoxemiaTranslational Research, 2006
- Bidirectional Relation Between Inflammation and CoagulationCirculation, 2004